Phase 1/2 Trial Set to Test RGX-202, Gene Therapy for Duchenne MD

Phase 1/2 Trial Set to Test RGX-202, Gene Therapy for Duchenne MD

316103

Phase 1/2 Trial Set to Test RGX-202, Gene Therapy for Duchenne MD

The U.S. Food and Drug Administration (FDA) has approved Regenxbio’s request to launch a Phase 1/2 clinical trial in the U.S. evaluating the safety and efficacy of RGX-202, its experimental gene therapy for Duchenne muscular dystrophy (DMD). The study, called AFFINITY DUCHENNE and anticipated to start in the coming months, will test the one-time therapy in children with DMD who can walk unaided. Information on contacts and locations is not yet available, but initial trial…

You must be logged in to read/download the full post.